Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/8160
|
| Title: | Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma |
| Authors: | Tsai, HJ;Lin, SF;Chen, CC;Chen, TY;Su, WC;Hwang, WL;Lin, JC;Chiou, TJ;Kao, WY;Chiu, CF;Chang, YF;Chang, JS;Chang, MC;Su, IJ |
| Contributors: | National Institute of Cancer Research;Division of Biostatistics and Bioinformatics;Division of Infectious Diseases |
| Abstract: | PURPOSE: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of front-line concurrent chemo-radiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). PATIENTS AND METHODS: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included 2 cycles of the DEP regimen (dexamethasone, etoposide plus cisplatin) every 4 weeks with concurrent 5,040 cGy radiation in 28 fractions for 5 weeks. Patients without disease progression after CCRT were subjected to 2 cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna and cisplatin every 4 weeks. The primary endpoint was tumor response rate and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). RESULTS: Thirty-three patients received CCRT and 29 patients received 2 cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-year and 5-year progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). CONCLUSION: Front-line CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL. |
| Date: | 2015-02 |
| Relation: | European Journal of Haematology. 2015 Feb;94(2):130-137. |
| Link to: | http://dx.doi.org/10.1111/ejh.12405 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0902-4441&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000350099700007 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84922846170 |
| Appears in Collections: | [張書銘] 期刊論文
[蔡慧珍] 期刊論文
[陳主智] 期刊論文
[蘇益仁(2002-2015)] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB24957163.pdf | | 147Kb | Adobe PDF | 618 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
